Digital Marketing Company for Sale

New Developments in Fight Against Blood Cancers, in Leadup to US$17.1 Billion Market by 2024

Vancouver, British ColumbiaAnd January 10 2022 /PRNewswire/- United States of America News Group – Nearly 10% of the estimated 1.9 million new cancer cases in North America United States of America He will be diagnosed with leukemia, lymphoma, and myeloma. According to analysts at Markets and Markets, the blood cancer treatment market is expected to reach 17.1 billion US dollars By 2024, at a compound annual growth rate of 6.8%. Along the way, there have been many positive developments in the fight against blood cancers including more recent updates from Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), AbbVie Inc. (NYSE: ABBV), Novartis AG (NYSE: NVS), Thermo Fisher Scientific Inc. (NYSE: TMO), and NeoGeonomics, Inc. (NASDAQ: NEO).

By treatment with the leading immunotherapy agent pelareorep, Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) recently announced preclinical data demonstrating synergistic anti-leukemia effects when combined with the chemotherapeutic agent azacitidine.

Thomas Heinemann, MD, global head of clinical development, said: “These compelling preclinical findings, together with previously reported data demonstrating clinical proof-of-concept for multiple myeloma, indicate that the immunotherapy effects of pelareorep extend across Many hematological malignancies. and operations in Oncolytic. “It also highlights the ability of bellariorib to enhance the efficacy of a wide range of cancer treatments, and has stimulated interest in investigator-sponsored clinical studies of bellariorib in leukemia.”

Bellariorib has shown synergism with immune checkpoint inhibitors and may also be synergistic with other approved oncology therapies, as demonstrated with these recent preclinical findings.

Compared with either treatment alone, treatment with pelareorep plus azacitidine resulted in a statistically significant (p < 0.01) reduction in tumor burden in a xenograft mouse model of leukemia.

Compared with either treatment alone, treatment with pelareorep plus azacitidine resulted in a statistically significant (p < 0.001) synergistic enhancement of anti-leukemic activity against AML cell lines, a benefit that was confirmed in samples of AML patients. in the laboratory.

The combination of pelareorep and azacitidine significantly upregulated multiple genes known to stimulate anticancer immune responses such as IFNβ1, BATF2, IL-12β, CCL2, TLR3, And PD-L1.

Intravenously delivered pelareorep stimulates anticancer immune responses and enhances the inflamed tumor phenotype–the conversion of ‘cold’ to ‘hot’ tumors–through innate and adaptive immune responses to treat a variety of cancers.

Oncolytic Clinical trials are underway and planned to evaluate pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as they progress toward a registry study in metastatic breast cancer.

For some leukemia patients, new research confirms that long periods of remission occur after treatment with the drug ibrutinib AbbVie Inc. (NYSE: ABBV) with chemotherapy.

The study included 85 patients (all 65 years of age or younger) with chronic lymphocytic leukemia (CLL), in which 46 patients showed a more aggressive IGHV subtype of the disease.

Dr. said. Matthew Davids, from the Dana-Farber Cancer Institute in Boston. “Our study examined whether a limited time course of ibrutinib given in combination with a FCR could provide permanent remissions for patients with CLL regardless of whether they had a mutated or undeveloped subtype of IGHV.”

Study participants received ibrutinib for seven days, followed by a combination of ibrutinib and FCR for up to six months. They continued receiving ibrutinib alone for another two years, and stopped taking the drug when they had no detectable leukemia cells in their bone marrow after two years.

Novartis AG (NYSE:NVS) is pressing ahead with its cancer development efforts, having recently shared positive results from two ongoing trials for lymphoma and leukemia.

During ASCEMBL’s Phase III study of Scemblix (asciminib) in patients diagnosed with Philadelphia In the chronic phase, chromosome-positive CML, the drug showed that it was able to survive longer before needing follow-up compared to Bosulev (bosutinib).

In comparison, Scemblix provided a significant molecular response (MMR) rate of 29.3% at 48 weeks versus 13% for those who received Bosulif.

Results at Week 48 were consistent with a doubling of drug efficacy at Week 4, reporting a 25% MMR versus Bosulif’s 13%. In addition, patients experienced fewer adverse reactions in the Scemblix group, 7.1% versus 25%.

Novartis It also reported that the candidate drug for treatment of follicular lymphoma (FL), Kymriah (tisagenlecleucel), showed strong efficacy during follow-up about 17 months after the phase 2 trial of ELARA.

The researchers found that Kymriah delivered high rates of durable responses in the majority of high-risk disease subgroups that, otherwise, would have a poor prognosis. Novartis It already submitted applications for approval with regulators in the European Union and the United States in October. Once approved, the company will bring its research to a real-world level.

A leading provider of cancer-focused genetic testing services and global oncology contract research service providers NeoGeonomics, Inc. (NASDAQ:NEO) recently announced that it will use the Ion Torrent Genexus System, from Thermo Fisher Scientific Inc. (NYSE: TMO).

Ion Torrent Genexus is the first turnkey Next Generation Serialization (NGS) solution that automates sample-to-report workflows to deliver results in less than one day

We worked with Thermo Fisher Scientific In their many genomic initiatives, we are excited to leverage their Genexus system to deliver comprehensive genomic data at an unprecedented speed.” Mark Malone, CEO of NeoGenomics. “By compressing the time it takes to get results from weeks to days, we can ensure researchers have the data they need to accelerate progress as they look to develop much-needed marrow cancer therapies in the future.”

As part of a preclinical research investigation, NeoGenomics He will get early access to Thermos Fisher New Oncomine Myeloid Assay GX v2 for assay validation on the Genexus system. The test is designed to improve variant detection, covering key genes and fusions across the myeloid cancer spectrum.

“Spinal cord cancers such as acute myeloid leukemia present unique challenges due to their heterogeneity and sample complexity,” Garrett HamptonHead of the Department of Clinical Sequencing and Oncology, Thermo Fisher Scientific. “NGS allows researchers to identify all major mutations simultaneously, saving time compared to sequencing single-gene testing. By combining the speed of the Genexus system with NeoGenomics“Experience and data services, we hope to advance discoveries that will inform future therapeutic development for patients who are most in need of new treatment options.”

For more information, please visit the website:

Article source:

United States of America newsgroup
[email protected]

Disclaimer: Nothing in this post should be considered personal financial advice. We are not authorized under the securities laws to deal with your particular financial situation. No communication by our employees to you should be considered as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is not an offer or recommendation to buy or sell any security. We do not hold any investment licenses and are therefore not licensed or qualified to provide investment advice. The content in this report or email is not provided to any individual in order to deal with their individual circumstances. United States of America News Group is a wholly owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ paid for advertising on Oncolytics Biotech Inc. and digital media directly from the company. There may be third parties who may have shares in Oncolytics Biotech Inc. They may liquidate their shares, which may have a negative impact on the share price. This indemnity constitutes a conflict of interest regarding our ability to maintain objectivity in our communications with respect to the identified company. Because of this conflict, we strongly encourage individuals not to use this post as a basis for any investment decision. The owner/operator of MIQ owns shares of Oncolytics Biotech Inc. purchased on the open market, and reserves the right to buy and sell, and will buy and sell shares of Oncolytics Biotech Inc. at any time without any further notice commences immediately and continues. We also expect additional compensation as an ongoing digital media effort to increase company visibility, and no further notice will be given, but let this disclaimer serve as notice that all material, including this article, published by MIQ has been approved by the biotech company Oncolytics; This is a paid advertisement, we currently own shares of Oncolytics Biotech Inc. We will buy and sell Company shares on the open market, or through special offers and/or other investment vehicles.

While all information is believed to be reliable, we cannot guarantee its accuracy. Individuals should assume that all information in our newsletter is not trustworthy unless verified by their own independent research. Also, since events and conditions do not occur as frequently as expected, there are likely to be discrepancies between any predictions and actual outcomes. Always consult a licensed investment expert before making any investment decision. Be very careful, investing in securities carries a high level of risk; You will likely lose some or all of your investment.

United States of America The newsgroup is the source for all of the above content. FN Media Group, LLC (FNM), is an external publisher and news dissemination service provider, which disseminates electronic information through various online media channels. FNM is not affiliated in any way with the USA News Group or any company mentioned herein. The comments, views, and opinions expressed in this statement by USA News Group are solely those of USA News Group and are not shared by and do not in any way reflect the views or opinions of FNM. FNM is not responsible for any investment decisions made by its readers or subscribers. FNM and its affiliates are a provider of news publishing and financial marketing solutions and are not a registered broker/dealer/analyst/advisor, do not hold any investment licenses and may not sell, offer to sell or offer to buy any security. FNM has not been compensated by any public company mentioned herein for publishing this press release.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made in accordance with the provisions of the Securities Litigation Reform Act 1995 financial year. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may,” “future,” “plan,” “planned,” “will,” “should,” “expect,” “expects,” Expected”, “draft”, “ultimate” or “expected”. You are cautioned that such statements are subject to many risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements, including risks that could cause actual results to differ materially from those projected in the forward-looking statements as a result of for various factors, and other risks identified in the company’s annual report on Form 10-K or 10-KSB and other filings that that company has filed with the Securities and Exchange Commission. You should take these factors into account when evaluating the forward-looking statements contained herein, and not place undue reliance on such statements. The forward-looking statements contained in this statement were made as of the date of this release and FNM does not undertake any obligation to update such statements.

SOURCE USA newsgroup

source United States of America newsgroup


About the author

publishing team